185 related articles for article (PubMed ID: 34983615)
1. SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma.
Du L; Liu W; Aldana-Masangkay G; Pozhitkov A; Pichiorri F; Chen Y; Rosen ST
J Exp Clin Cancer Res; 2022 Jan; 41(1):8. PubMed ID: 34983615
[TBL] [Abstract][Full Text] [Related]
2. SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide.
Du L; Liu W; Pichiorri F; Rosen ST
Cancer Gene Ther; 2023 Apr; 30(4):567-574. PubMed ID: 35338347
[TBL] [Abstract][Full Text] [Related]
3. miR-221/222-Mediated Inhibition of Autophagy Promotes Dexamethasone Resistance in Multiple Myeloma.
Xu J; Su Y; Xu A; Fan F; Mu S; Chen L; Chu Z; Zhang B; Huang H; Zhang J; Deng J; Ai L; Sun C; Hu Y
Mol Ther; 2019 Mar; 27(3):559-570. PubMed ID: 30765325
[TBL] [Abstract][Full Text] [Related]
4. LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway.
Wu Y; Wang H
J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29205703
[TBL] [Abstract][Full Text] [Related]
5. Diallyl thiosulfinate enhanced the anti-cancer activity of dexamethasone in the side population cells of multiple myeloma by promoting miR-127-3p and deactivating the PI3K/AKT signaling pathway.
He W; Fu Y; Zheng Y; Wang X; Liu B; Zeng J
BMC Cancer; 2021 Feb; 21(1):125. PubMed ID: 33549034
[TBL] [Abstract][Full Text] [Related]
6. HMGB1 knockdown increases MM cell vulnerability by regulating autophagy and DNA damage repair.
Guo X; He D; Zhang E; Chen J; Chen Q; Li Y; Yang L; Yang Y; Zhao Y; Wang G; He J; Cai Z
J Exp Clin Cancer Res; 2018 Aug; 37(1):205. PubMed ID: 30157958
[TBL] [Abstract][Full Text] [Related]
7. Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma.
Sriskandarajah P; De Haven Brandon A; MacLeod K; Carragher NO; Kirkin V; Kaiser M; Whittaker SR
BMC Cancer; 2020 Mar; 20(1):269. PubMed ID: 32228485
[TBL] [Abstract][Full Text] [Related]
8. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.
Zhao JJ; Chu ZB; Hu Y; Lin J; Wang Z; Jiang M; Chen M; Wang X; Kang Y; Zhou Y; Ni Chonghaile T; Johncilla ME; Tai YT; Cheng JQ; Letai A; Munshi NC; Anderson KC; Carrasco RD
Cancer Res; 2015 Oct; 75(20):4384-4397. PubMed ID: 26249174
[TBL] [Abstract][Full Text] [Related]
9. In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.
Neri P; Yasui H; Hideshima T; Tassone P; Raje N; Catley LP; Ishitsuka K; Blotta S; Kiziltepe T; Ocio EM; Fulciniti M; Kanekal S; Elliott GT; Munshi NC; Anderson KC
Br J Haematol; 2006 Jul; 134(1):37-44. PubMed ID: 16803565
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells.
Clarisse D; Prekovic S; Vlummens P; Staessens E; Van Wesemael K; Thommis J; Fijalkowska D; Acke G; Zwart W; Beck IM; Offner F; De Bosscher K
Cell Mol Life Sci; 2023 Aug; 80(9):249. PubMed ID: 37578563
[TBL] [Abstract][Full Text] [Related]
11. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells.
Gazitt Y; Fey V; Thomas C; Alvarez R
Int J Oncol; 1998 Aug; 13(2):397-405. PubMed ID: 9664139
[TBL] [Abstract][Full Text] [Related]
12. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
13. SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma.
Heynen GJJE; Baumgartner F; Heider M; Patra U; Holz M; Braune J; Kaiser M; Schäffer I; Bamopoulos SA; Ramberger E; Murgai A; Ng YLD; Demel UM; Laue D; Liebig S; Krüger J; Janz M; Nogai A; Schick M; Mertins P; Müller S; Bassermann F; Krönke J; Keller U; Wirth M
Blood Adv; 2023 Feb; 7(4):469-481. PubMed ID: 35917568
[TBL] [Abstract][Full Text] [Related]
14. miR-137 Suppresses the Phosphorylation of AKT and Improves the Dexamethasone Sensitivity in Multiple Myeloma Cells Via Targeting MITF.
Zhang B; Ma L; Wei J; Hu J; Zhao Z; Wang Y; Chen Y; Zhao F
Curr Cancer Drug Targets; 2016; 16(9):807-817. PubMed ID: 26845432
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.
Lund J; Gruber A; Lauri B; Duru AD; Blimark C; Swedin A; Hansson M; Forsberg K; Ahlberg L; Carlsson C; Waage A; Gimsing P; Vangsted AJ; Frølund U; Holmberg E; Gahrton G; Alici E; Hardling M; Mellqvist UH; Nahi H
Cancer Med; 2018 Jun; 7(6):2256-2268. PubMed ID: 29673108
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone inhibits stemness maintenance and enhances chemosensitivity of hepatocellular carcinoma stem cells by inducing deSUMOylation of HIF‑1α and Oct4.
Jiang Z; Zhang C; Liu X; Ma X; Bian X; Xiao X; Gao R; Sun Y; Wu W; Zhao P
Int J Oncol; 2020 Sep; 57(3):780-790. PubMed ID: 32705164
[TBL] [Abstract][Full Text] [Related]
17. Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma.
Kervoëlen C; Ménoret E; Gomez-Bougie P; Bataille R; Godon C; Marionneau-Lambot S; Moreau P; Pellat-Deceunynck C; Amiot M
Oncotarget; 2015 Sep; 6(29):26922-34. PubMed ID: 26323097
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoid effects on myeloma cells in culture: correlation of growth inhibition with induction of glucocorticoid receptor messenger RNA.
Gomi M; Moriwaki K; Katagiri S; Kurata Y; Thompson EB
Cancer Res; 1990 Mar; 50(6):1873-8. PubMed ID: 2106390
[TBL] [Abstract][Full Text] [Related]
19. Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesis.
Bera S; Greiner S; Choudhury A; Dispenzieri A; Spitz DR; Russell SJ; Goel A
Neoplasia; 2010 Dec; 12(12):980-92. PubMed ID: 21170263
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-9 regulates steroid-resistant airway hyperresponsiveness by reducing protein phosphatase 2A activity.
Li JJ; Tay HL; Maltby S; Xiang Y; Eyers F; Hatchwell L; Zhou H; Toop HD; Morris JC; Nair P; Mattes J; Foster PS; Yang M
J Allergy Clin Immunol; 2015 Aug; 136(2):462-73. PubMed ID: 25772595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
